NOVARTIS Stock Analysis

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NI</div>
NOVARTIND -- India Stock  

INR 573.25  4.95  0.87%

Is it time to buy NOVARTIS INDIA? NOVARTIS INDIA Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The latest bullish price patterns experienced by current NOVARTIS INDIA LTD shareholders may encourage investors to take a closer look at the firm as it closed today at a share price of 566.45001221 on very low momentum in trading volume. The company directors and management have been very successful with rebalancing the firm assets at opportune times to take advantage of market volatility in May. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 3.78. The above-average volatility is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from NOVARTIS INDIA LTD partners. Additionally, see Stocks Correlation.

Search Stock Analysis

 
Refresh
The NOVARTIS INDIA Stock analysis interface makes it easy to digest most current publicly released information about NOVARTIS INDIA as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. NOVARTIS stock analysis module also helps to analyze NOVARTIS INDIA price relationship with some important fundamental indicators such as market cap and management efficiency.

NOVARTIS Stock Analysis Notes

The company has price-to-book ratio of 1.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NOVARTIS INDIA LTD recorded earning per share (EPS) of 9.26. The entity last dividend was issued on 2019-07-31. Novartis India Limited primarily trades in drugs and pharmaceuticals. The company was incorporated in 1947 and is headquartered in Mumbai, India. NOVARTIS INDIA operates under Drug ManufacturersSpecialty Generic classification in India and is traded on Bombay Stock Exchange. It employs 581 people. To find out more about N/A contact the company at 91 22 5024 3000 or learn more at http://www.novartis.in.

NOVARTIS INDIA LTD Investment Alerts

NOVARTIS INDIA LTD has very high historical volatility over the last 30 days
N/A has accumulated about 6.49 B in cash with (283.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 262.92.

Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 13.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NOVARTIS INDIA's market, we take the total number of it shares issued and multiply it by the NOVARTIS INDIA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Profitablity

The company has Profit Margin (PM) of 5.02 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is normal as compared to the sector avarege. Similarly, it shows Operating Margin (OM) of 3.05 % which suggests for every 100 dollars of sales it generated a net operating income of 0.03.

Management Efficiency

The entity has return on total asset (ROA) of 1.23 % which means that it generated profit of $1.23 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 3.86 % meaning that it generated $3.86 on every $100 dollars invested by stockholders. NOVARTIS INDIA management efficiency ratios could be used to measure of how well novartis india ltd is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.

Technical Drivers

As of the 31st of May NOVARTIS INDIA secures Risk Adjusted Performance of (0.21), Market Risk Adjusted Performance of 5.4 and Mean Deviation of 2.07. Concerning Fundamental Indicators, Macroaxis technical analysis interface lets you check available technical drivers of NOVARTIS INDIA LTD as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices or the prices will eventually revert. We found nineteen technical drivers for NOVARTIS INDIA, which can be compared to its peers in the industry. Please verify NOVARTIS INDIA LTD Jensen Alpha and Downside Variance to decide if NOVARTIS INDIA LTD is priced favorably providing market reflects its recent price of 573.25 per share.

NOVARTIS INDIA LTD Price Movement Analysis

Study
The minimum time period for execution of this function requires larger time horizon. Please increase the time horizon for this function. The output start index for this execution was zero with a total number of output elements of zero. The Instantaneous Trendline is a moving-average-like indicator which is formed by removing the Dominant Cycle from NOVARTIS INDIA LTD price series. View also all equity analysis or get more info about hilbert transform instantaneous trendline overlap studies indicator.

NOVARTIS INDIA Technical and Predictive Indicators

NOVARTIS INDIA Forecast Models

Did you try this?

Run Portfolio Center Now

   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module
Additionally, see Stocks Correlation. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page